[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Neurocrine Switzerland GmbH\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":45},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100634175","phase-2-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-crinecerfont-in-participants-with-classic-congenital-adrenal-hyperplasia-cah-who-are-less-than-4-years-old-100634175",false,"NCT07536269","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old","A Phase 2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Crinecerfont in Pediatric Participants 3 Months to \u003C4 Years of Age With Classic Congenital Adrenal Hyperplasia","Key Inclusion Criteria:\n\n* Have a medically confirmed diagnosis of classic CAH (salt wasting or simple virilizing) due to 21-hydroxylase deficiency (21-OHD)\n* Have received at least 3 months of hydrocortisone treatment before Day 1, with a stable dose for at least 4 weeks before screening.\n* Have a body weight of at least 4.5 kilograms (kg) at screening.\n* Have a newborn screen that is otherwise normal except for elevated 17-OHP or any other abnormality on newborn screen that was cleared upon evaluation by a pediatric specialist.\n\nKey Exclusion Criteria:\n\n* Have a known or suspected diagnosis of any of the other forms of classic CAH.\n* Have any condition besides CAH that requires chronic daily therapy with orally administered steroids.\n* Have any other clinically significant medical condition or chronic disease.\n\nNote: Other protocol-defined inclusion and exclusion criteria may apply.","ALL","3 Months","47 Months",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The main objective of this study is to assess the safety and tolerability of crinecerfont in pediatric participants 3 months to \\\u003C4 years of age with CAH.",[27],"Congenital Adrenal Hyperplasia",[27,29,30,31],"CAH","Crinecerfont","Pediatric","RECRUITING","2026-09-14",{"date":35,"type":36},"2026-09-16","ACTUAL",{"date":38,"type":36},"2026-07-01",{"date":40,"type":21},"2028-03",{"name":42,"class":43},"Neurocrine Switzerland GmbH","INDUSTRY",11,""]